# DoubleVerify Holdings, Inc.: financial statements, quarterly

DV · NYSE · CIK 1819928 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dv.md) · [Financials](/companies/dv/financials.md) · [Filings](/companies/dv/filings.md) · [Insiders](/companies/dv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [144](/filings/0001558370-24-014636.md) | [172 d](/filings/0001104659-26-020499.md) | [141](/filings/0001558370-25-006973.md) | [156](/filings/0001558370-25-010293.md) | [170](/filings/0001104659-25-108136.md) | [191 d](/filings/0001104659-26-020499.md) | [165](/filings/0001104659-26-056250.md) | [189](/filings/0001104659-26-092375.md) | [189](/filings/0001104659-25-108136.md) | [206 d](/filings/0001104659-26-020499.md) | [181](/filings/0001104659-26-056250.md) | [194](/filings/0001104659-26-092375.md) |
| Cost of revenue | $m | [26.5](/filings/0001558370-24-014636.md) | [30.0 d](/filings/0001104659-26-020499.md) | [26.6](/filings/0001558370-25-006973.md) | [26.1](/filings/0001558370-25-010293.md) | [29.5](/filings/0001104659-25-108136.md) | [34.3 d](/filings/0001104659-26-020499.md) | [31.0](/filings/0001104659-26-056250.md) | [33.1](/filings/0001104659-26-092375.md) | [33.5](/filings/0001104659-25-108136.md) | [35.9 d](/filings/0001104659-26-020499.md) | [33.2](/filings/0001104659-26-056250.md) | [32.5](/filings/0001104659-26-092375.md) |
| Research and development | $m | [32.3](/filings/0001558370-24-014636.md) | [32.6 d](/filings/0001104659-26-020499.md) | [36.4](/filings/0001558370-25-006973.md) | [39.8](/filings/0001558370-25-010293.md) | [39.3](/filings/0001104659-25-108136.md) | [37.5 d](/filings/0001104659-26-020499.md) | [44.7](/filings/0001104659-26-056250.md) | [47.2](/filings/0001104659-26-092375.md) | [44.8](/filings/0001104659-25-108136.md) | [41.7 d](/filings/0001104659-26-020499.md) | [45.4](/filings/0001104659-26-056250.md) | [46.4](/filings/0001104659-26-092375.md) |
| Operating income | $m | [18.2](/filings/0001558370-24-014636.md) | [37.6 d](/filings/0001104659-26-020499.md) | [6.9](/filings/0001558370-25-006973.md) | [11.0](/filings/0001558370-25-010293.md) | [25.7](/filings/0001104659-25-108136.md) | [38.8 d](/filings/0001104659-26-020499.md) | [6.8](/filings/0001104659-26-056250.md) | [13.5](/filings/0001104659-26-092375.md) | [21.1](/filings/0001104659-25-108136.md) | [37.8 d](/filings/0001104659-26-020499.md) | [15.6](/filings/0001104659-26-056250.md) | [23.0](/filings/0001104659-26-092375.md) |
| Interest expense | $m | [0.3](/filings/0001558370-24-014636.md) | [0.3 d](/filings/0001104659-26-020499.md) | [0.2](/filings/0001558370-25-006973.md) | [0.2](/filings/0001558370-25-010293.md) | [0.4](/filings/0001104659-25-108136.md) | [0.3 d](/filings/0001104659-26-020499.md) | [0.4](/filings/0001104659-26-056250.md) | [0.4](/filings/0001104659-26-092375.md) | [0.5](/filings/0001104659-25-108136.md) | [0.4 d](/filings/0001104659-26-020499.md) | [0.4](/filings/0001104659-26-056250.md) | [0.5](/filings/0001104659-26-092375.md) |
| Income tax | $m | [6.2](/filings/0001558370-24-014636.md) | [8.6 d](/filings/0001104659-26-020499.md) | [1.8](/filings/0001558370-25-006973.md) | [5.4](/filings/0001558370-25-010293.md) | [11.4](/filings/0001104659-25-108136.md) | [14.0 d](/filings/0001104659-26-020499.md) | [7.2](/filings/0001104659-26-056250.md) | [6.5](/filings/0001104659-26-092375.md) | [10.3](/filings/0001104659-25-108136.md) | [8.1 d](/filings/0001104659-26-020499.md) | [7.8](/filings/0001104659-26-056250.md) | [9.0](/filings/0001104659-26-092375.md) |
| Net income | $m | [13.3](/filings/0001558370-24-014636.md) | [33.1 d](/filings/0001104659-26-020499.md) | [7.2](/filings/0001104659-25-108136.md) | [7.5](/filings/0001104659-25-108136.md) | [18.2](/filings/0001104659-25-108136.md) | [23.4 d](/filings/0001104659-26-020499.md) | [2.4](/filings/0001104659-26-092375.md) | [8.8](/filings/0001104659-26-092375.md) | [10.2](/filings/0001104659-25-108136.md) | [29.3 d](/filings/0001104659-26-020499.md) | [6.4](/filings/0001104659-26-092375.md) | [12.9](/filings/0001104659-26-092375.md) |
| Diluted EPS | $ per share | [0.08](/filings/0001558370-24-014636.md) | not reported | [0.04](/filings/0001558370-25-006973.md) | [0.04](/filings/0001558370-25-010293.md) | [0.10](/filings/0001104659-25-108136.md) | not reported | [0.01](/filings/0001104659-26-056250.md) | [0.05](/filings/0001104659-26-092375.md) | [0.06](/filings/0001104659-25-108136.md) | not reported | [0.04](/filings/0001104659-26-056250.md) | [0.08](/filings/0001104659-26-092375.md) |
| Basic EPS | $ per share | [0.08](/filings/0001558370-24-014636.md) | not reported | [0.04](/filings/0001558370-25-006973.md) | [0.04](/filings/0001558370-25-010293.md) | [0.11](/filings/0001104659-25-108136.md) | not reported | [0.01](/filings/0001104659-26-056250.md) | [0.05](/filings/0001104659-26-092375.md) | [0.06](/filings/0001104659-25-108136.md) | not reported | [0.04](/filings/0001104659-26-056250.md) | [0.08](/filings/0001104659-26-092375.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [259](/filings/0001558370-24-014636.md) | [310](/filings/0001104659-26-020499.md) | [302](/filings/0001558370-25-006973.md) | [256](/filings/0001558370-25-010293.md) | [312](/filings/0001104659-25-108136.md) | [293](/filings/0001104659-26-020499.md) | [156](/filings/0001104659-26-056250.md) | [212](/filings/0001104659-26-092375.md) | [201](/filings/0001104659-25-108136.md) | [259](/filings/0001104659-26-092375.md) | [174](/filings/0001104659-26-056250.md) | [210](/filings/0001104659-26-092375.md) |
| Current assets | $m | [469](/filings/0001558370-23-018618.md) | [533](/filings/0001558370-25-001814.md) | [550](/filings/0001558370-24-007053.md) | [560](/filings/0001558370-24-010381.md) | [580](/filings/0001558370-24-014636.md) | [559](/filings/0001104659-26-020499.md) | [422](/filings/0001558370-25-006973.md) | [462](/filings/0001558370-25-010293.md) | [477](/filings/0001104659-25-108136.md) | [519](/filings/0001104659-26-092375.md) | [451](/filings/0001104659-26-056250.md) | [471](/filings/0001104659-26-092375.md) |
| Total assets | $m | [1,175](/filings/0001558370-23-018618.md) | [1,243](/filings/0001558370-25-001814.md) | [1,260](/filings/0001558370-24-007053.md) | [1,273](/filings/0001558370-24-010381.md) | [1,312](/filings/0001558370-24-014636.md) | [1,276](/filings/0001104659-26-020499.md) | [1,249](/filings/0001558370-25-006973.md) | [1,297](/filings/0001558370-25-010293.md) | [1,296](/filings/0001104659-25-108136.md) | [1,354](/filings/0001104659-26-092375.md) | [1,274](/filings/0001104659-26-056250.md) | [1,310](/filings/0001104659-26-092375.md) |
| Current liabilities | $m | [74.8](/filings/0001558370-23-018618.md) | [83.9](/filings/0001558370-25-001814.md) | [75.4](/filings/0001558370-24-007053.md) | [79.5](/filings/0001558370-24-010381.md) | [88.2](/filings/0001558370-24-014636.md) | [103](/filings/0001104659-26-020499.md) | [114](/filings/0001558370-25-006973.md) | [105](/filings/0001558370-25-010293.md) | [120](/filings/0001104659-25-108136.md) | [122](/filings/0001104659-26-092375.md) | [94.6](/filings/0001104659-26-056250.md) | [105](/filings/0001104659-26-092375.md) |
| Total liabilities | $m | [164](/filings/0001558370-23-018618.md) | [169](/filings/0001558370-25-001814.md) | [163](/filings/0001558370-24-007053.md) | [167](/filings/0001558370-24-010381.md) | [182](/filings/0001558370-24-014636.md) | [193](/filings/0001104659-26-020499.md) | [217](/filings/0001558370-25-006973.md) | [207](/filings/0001558370-25-010293.md) | [220](/filings/0001104659-25-108136.md) | [223](/filings/0001104659-26-092375.md) | [193](/filings/0001104659-26-056250.md) | [216](/filings/0001104659-26-092375.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,011](/filings/0001558370-24-014636.md) | [1,074](/filings/0001104659-26-020499.md) | [1,097](/filings/0001104659-25-108136.md) | [1,105](/filings/0001104659-25-108136.md) | [1,131](/filings/0001104659-25-108136.md) | [1,083](/filings/0001104659-26-092375.md) | [1,032](/filings/0001104659-26-092375.md) | [1,090](/filings/0001104659-26-092375.md) | [1,076](/filings/0001104659-25-108136.md) | [1,131](/filings/0001104659-26-092375.md) | [1,081](/filings/0001104659-26-092375.md) | [1,094](/filings/0001104659-26-092375.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [35.5 d](/filings/0001558370-24-014636.md) | [52.1 d](/filings/0001104659-26-020499.md) | [31.8](/filings/0001558370-25-006973.md) | [35.9 d](/filings/0001558370-25-010293.md) | [54.6 d](/filings/0001104659-25-108136.md) | [37.4 d](/filings/0001104659-26-020499.md) | [37.7](/filings/0001104659-26-056250.md) | [49.6 d](/filings/0001104659-26-092375.md) | [51.2 d](/filings/0001104659-25-108136.md) | [72.7 d](/filings/0001104659-26-020499.md) | [4.2](/filings/0001104659-26-056250.md) | [76.2 d](/filings/0001104659-26-092375.md) |
| Capital expenditure | $m | [4.6 d](/filings/0001558370-24-014636.md) | [4.7 d](/filings/0001104659-26-020499.md) | [6.4](/filings/0001558370-25-006973.md) | [7.2 d](/filings/0001558370-25-010293.md) | [6.2 d](/filings/0001104659-25-108136.md) | [7.4 d](/filings/0001104659-26-020499.md) | [6.3](/filings/0001104659-26-056250.md) | [9.5 d](/filings/0001104659-26-092375.md) | [12.1 d](/filings/0001104659-25-108136.md) | [10.6 d](/filings/0001104659-26-020499.md) | [10.5](/filings/0001104659-26-056250.md) | [10.5 d](/filings/0001104659-26-092375.md) |
| Share repurchases | $m | [0.9 d](/filings/0001558370-23-018618.md) | [0.9 d](/filings/0001558370-24-002008.md) | [1.8](/filings/0001558370-24-007053.md) | [23.2 d](/filings/0001558370-25-010293.md) | [25.0 d](/filings/0001104659-25-108136.md) | [77.9 d](/filings/0001104659-26-020499.md) | [82.2](/filings/0001104659-26-056250.md) | [0.0 d](/filings/0001104659-26-092375.md) | [50.1 d](/filings/0001104659-25-108136.md) | [0.0 d](/filings/0001104659-26-020499.md) | [75.1](/filings/0001104659-26-056250.md) | [25.1 d](/filings/0001104659-26-092375.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [171](/filings/0001558370-23-018618.md) | [172](/filings/0001558370-24-007053.md) | [172](/filings/0001558370-24-010381.md) | [174](/filings/0001558370-24-014636.md) | [176](/filings/0001558370-25-006973.md) | [176](/filings/0001558370-25-010293.md) | [174](/filings/0001104659-25-108136.md) | [169](/filings/0001104659-26-056250.md) | [167](/filings/0001104659-26-092375.md) | [166](/filings/0001104659-25-108136.md) | [164](/filings/0001104659-26-056250.md) | [158](/filings/0001104659-26-092375.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 154,986,847 at 2026-07-29, from the cover of the [10-Q filed 2026-08-07](/filings/0001104659-26-092375.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.